pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Rare Disease · news · pharmadog
← back to Rare Disease
News mentioning Rare Disease
345
stories
9h
Shionogi pays $2B to acquire a rare disease startup
biopharma dive
10h
Lilly doubles down on Gate alliance to unlock new drug class with another $870M+ in biobucks
biospace
10h
Shionogi to pay $2B for IntraBio, a commercial rare disease biotech
endpoints
11h
Biogen’s big lupus bet gets boost from new durability data for skin disease
biospace
12h
STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
stat
16h
Precision for All: Closing the gap between innovation and impact
biopharma dive
20h
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
20h
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
21h
Opinion: FDA must ensure American patients can access new and experimental drugs
biospace
3d
Foghorn cuts 40% of workforce
biospace
3d
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
biospace
4d
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
biospace
4d
US government launches AI-driven programs to overhaul clinical trials
biospace
4d
The race for access: How the FAIR Act could reclaim U.S. biotech leadership
biospace
4d
STAT+: In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the world
stat
5d
Atara, Pierre Fabre resubmit twice-rebuffed cell therapy after FDA flips again
biospace
5d
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
5d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
6d
Beam sues 2 biotechs, alleging theft of base editing trade secrets
biopharma dive
6d
STAT+: Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property
stat
6d
UniQure tumbles with latest data for Huntington’s gene therapy
biopharma dive
6d
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years
biospace
7d
Egetis Therapeutics' Emcitate cleared by FDA for rare X-linked genetic disease
endpoints
7d
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
biospace
7d
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat
biospace
10d
To get drugmakers into ultra-rare disease, the answer isn’t rare disease at all
endpoints
10d
Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
fiercebiotech
10d
Federal judge rolls back landmark disability protections
stat
10d
Travere CEO Eric Dube on deciding to leave; Roche tees up a board seat for ex-Takeda chief
endpoints
11d
US senators grill FDA nominee Overton on ability to ‘stand up’ to Trump
biospace
← prev
page 1 of 12
next →
